WiMi Hologram Cloud (NASDAQ:WIMI) Stock, Quote.Headers.trade-ideas

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

WIMI

News

Movers

Shares of WiMi Hologram Cloud Inc. (NASDAQ: WIMI) are trading higher Friday from possible continued momentum. The company announced a new development in quantum computing technology Thursday.

WiMi Hologram Shares Are Up Friday: What&#39;s Going On?

Equities

Markets

General

WiMi Hologram stock is rising after announcing its development of a Quantum Technology-Based Random Access Memory (QRAM) architecture.

WiMi Develops Quantum Technology-Based QRAM Architecture, Shares Surge

Tech

WiMi Hologram Cloud Inc. (NASDAQ: WIMI) shares rose 3.33% after unveiling its Machine Learning-based Quantum Error Suppression Technology (MLQES).





What&#39;s Going On With WiMi Hologram Cloud Stock On Tuesday?

WiMi Hologram Cloud Inc. - American Depositary Share

WiMi Hologram Cloud Inc

The Company is scheduled to present at the 2025 ICR Conference today, January 13, 2025, at 4:00 p.m. E.T.
To announce full third quarter fiscal year 2025 results on February 5, 2025 after market
BARK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BARK#NYSE">BARK</a>) ("BARK" or the "Company"), a leading global omnichannel dog brand with a mission to make all dogs happy, today announced its preliminary financial results for the fiscal third quarter ended December 31, 2024.
Preliminary Financial Results
<ul>
<li>Total revenue was approximately $126.4 million, ahead of the high-end of the Company's guidance range and a 1.1% increase, year-over-year.</li>
<li>Net loss of approximately $(11.5) million, was $1.4 million greater than the same period last year primarily related to a $1.8 million gain from the extinguishment of debt in the year-ago period.</li>
<li>Adjusted EBITDA was approximately $(1.6) million, within the Company's guidance range and a $4.9 million improvement, year-over-year.</li>
</ul>

Guidance

BARK

BARK Announces Preliminary Q3 2025 Results, Sees Revenue Up 1.1% To $126.4M; Net Loss Widened To $11.5M; Adjusted EBITDA Improved By $4.9M Year-Over-Year

SPNS

Sapiens Reports Availability Of SaaS Solutions In Microsoft Azure Marketplace

Ashford Hospitality Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) ("Ashford Trust" or the "Company") reported today that the Company expects to report Occupancy of approximately 66% for the fourth quarter of 2024 with Average Daily Rate of approximately $190 resulting in RevPAR of approximately $126. This Comparable RevPAR reflects an approximate increase of 3.0% compared to the fourth quarter of 2023.
Additionally, for the month of October 2024, Comparable RevPAR increased approximately 4.5% versus October 2023. For the month of November 2024, Comparable RevPAR increased approximately 0.4% versus November 2023. For the month of December 2024, Comparable RevPAR increased approximately 3.8% versus December 2023.

Ashford Trust Announces 66% Q4 2024 Occupancy With $190 Daily Rate, RevPAR Up 3% From Q4 2023

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.revvity.com&amp;esheet=54177303&amp;newsitemid=20250113006531&amp;lan=en-US&amp;anchor=Revvity%2C+Inc.&amp;index=1&amp;md5=62bc531096753544fd6dd613dca37631">Revvity, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.elementbiosciences.com%2F&amp;esheet=54177303&amp;newsitemid=20250113006531&amp;lan=en-US&amp;anchor=Element+Biosciences%2C+Inc.&amp;index=2&amp;md5=18278be0f4f95ece9bf56a33a9c51d70">Element Biosciences, Inc.</a>, a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.revvity.com%2Fpress-announcements%2Fpress-releases%2Fpress-release-details%2F2024%2FRevvity-Introduces-New-Workflow-to-Accelerate-Newborn-Sequencing-Research-%2Fdefault.aspx&amp;esheet=54177303&amp;newsitemid=20250113006531&amp;lan=en-US&amp;anchor=introduction&amp;index=3&amp;md5=11131fa9d8378e7e328b473cb5eb4c36">introduction</a> of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and strengthens Element's momentum towards regulatory approval of the benchtop <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.elementbiosciences.com%2Fproducts%2Faviti&amp;esheet=54177303&amp;newsitemid=20250113006531&amp;lan=en-US&amp;anchor=AVITI%26%238482%3B+sequencing+system&amp;index=4&amp;md5=78e2091ad474af5bd158f6593fad6048">AVITI&#x2122; sequencing system</a>.

RVTY

Revvity Partners with Element Biosciences to Develop Neonatal Sequencing Diagnostic Solution

<a href="https://www.globenewswire.com/Tracker?data=QICvUiLZeNOvfe6ZTx3s27EQ7dD4hI1hClQPV-1-39rw6P62jWvuIrW4UxkYTXClcz7J-fwcSeSdnMQ8PawaVS1kUy8179zk86G4Y9n1aQmPAiJIYp97pioLnz-4DRAYIKqDhaUUsApLUJcvIEEtf07Nf4OUrPMYeKbjXDZdg6SIU2YsU35AQzXZuCEzGjjbGABFxNCakcCUSfaFSrOHvwjxtV_OUM95u6okwf9QYB2mEwT72CqzhsFw1Fkei8DP8yQsiwQOBdgJzJM0VikYwZk5YrTAxXTX8M0CskikgaUJMJmlt9QYhmaby8-JAoJamtTZbIDZXqrgqFJFxq8fSCBg1IVanYMF6PcHImSICrEPk2VJIEDTBlBF6npaQdEEiHTPj1OCtMk0M961fU1AMfbWvTAxMA9Js2nZYl7iocjuWPfz4lusSv1kZUirQZw9DvbfYtu46-aw1e1HSpLpvpJnnSyL1BM6Z0FzWjt9G9N584A-suNw7j4WGhTVFRrG__JKKt-D5Sm2BrQSIN605sWLqGFyFahNJ9_hag8eIcY9Y3vlEzOe1JoQzuXwQatZBFlcJqRvTBFtKTT6oB7n1A==">LifeVantage Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFVN#NASDAQ">LFVN</a>), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, hosted its annual Global Kickoff on Saturday, January 11, 2025. Thousands of the company's independent Consultants around the world joined the live broadcast to celebrate the company's bold vision for 2025, which emphasized momentum, continued innovation, and international expansion of the MindBody GLP-1 System&#x2122;. The company also announced that the Philippines, Taiwan, Hong Kong, and Singapore markets will transition to the Evolve Compensation Plan on March 1, with Thailand, the final market to move to Evolve, planned for transition by the end of the fiscal year.
An energetic tone was set early in the broadcast by President and CEO Steve Fife, who introduced the 2025 theme: "Drive ERA." The theme's core message encourages Consultants to build on the momentum of the previous year, find their internal motivations, and take proactive control of their success.

Biotech

Global

LFVN

LifeVantage Announces 2025 Vision At Global Kickoff, Emphasizes MindBody GLP-1 System Expansion, Philippines, Taiwan, Hong Kong, Singapore To Transition To Evolve Plan On March 1, Thailand By Fiscal Year End

WIIM

ARQQ

LDTC

LWLG

NVDA

ONDS

VUZI

XTIA

Shares of semiconductor companies are trading lower. The Biden  Administration announced that it released an Interim Final Rule on Artificial Intelligence Diffusion that limits chip orders.

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and maintains $25 price target.

Price Target

Analyst Ratings

HUMA

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

New Commercial Supply Contracts for Vafseo&#xAE; (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S.
Vafseo tablets now shipping in the U.S.
Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients
Company to discuss business updates at 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4338898-1&amp;h=708505370&amp;u=http%3A%2F%2Fwww.akebia.com%2F&amp;a=Akebia+Therapeutics">Akebia Therapeutics</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4338898-1&amp;h=1449491289&amp;u=http%3A%2F%2Fwww.akebia.com%2F&amp;a=%C2%AE">&#xAE;</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4338898-1&amp;h=1945527750&amp;u=http%3A%2F%2Fwww.akebia.com%2F&amp;a=%2C+Inc.">, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced multiple positive business updates. As of January, Vafseo&#xAE; (vadadustat) tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease (CKD) on dialysis for at least three months, and shipment of product to dialysis centers has commenced. In addition, Akebia recently signed a Vafseo commercial supply agreement with a leading dialysis organization. Akebia now has contracts in place with dialysis organizations caring for nearly 100% of dialysis patients in the U.S. As previously announced, Vafseo qualifies for the Transitional Drug Add-On Payment Adjustment (TDAPA) reimbursement as directed by the Centers for Medicare &amp; Medicaid Services (CMS), and CMS has published billing guidance and reimbursement rates.<a href="https://mma.prnewswire.com/media/1136400/Akebia_Logo.html">AKBA</a>), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)"&gt;
Akebia also announced its plans to begin a Phase 3 trial for the use of vadadustat in treating anemia in late-stage CKD patients who are not on dialysis. Akebia received feedback from the U.S. Food and Drug Administration (FDA) on its protocol submission for a label expansion study and is incorporating feedback as appropriate. Akebia expects to begin the trial in mid-2025.

AKBA

Akebia Announced Near 100% U.S. Dialysis Coverage For Vafseo, Vafseo Shipments Commence, Phase 3 Trial For Late-Stage Non-Dialysis CKD Patients Planned for Mid-2025

Autolus Therapeutics plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces business updates and an overview of 2025 milestones.
"We enter 2025 with good momentum following the recent <a href="https://www.globenewswire.com/Tracker?data=DWdbHIS8rqnEROHXHOian0W_Zwu8p5JtLCfSpVn595fuyvJdyVnknnk_a8zwfxJr6O2v9JHkL8VwycWP9TyFZH-BEWpOpVNTTN3H0eH6WQBLL_mfIWbDbaiUO8QeOFzHJ6RdNSLLQ9LiK-_fC4wGx5xq8eupAWwYHJbZuaHla_22K0fLhL6wZdN2tsXBnK95OBEaoV_fjcsGuIO2enjYCvKsJuBBgtPmPKwM1Wm6QdicujFLo1jgQ8WJU4WgZAxSE8mVpeaDsN_se1HLFv7emA==">U.S. Food and Drug Administration (FDA) approval of AUCATZYL&#xAE;</a> (obecabtagene autoleucel, or "obe-cel") and <a href="https://www.globenewswire.com/Tracker?data=-GhGKHyHEkbh_o0NJlo12cymUmFmMtDfwESfLxsn11kyahL0O_SZoY8VvjPjqbuW-UVyazf3d5g2FpvBWrgJWjG7l678msOtV9bEIK_Calc1QuNBcAmYLBCPZRQ2GY0vkEQ5bCgXxF_TtiuHPRv3NLz_rlKy5BSv3Yyadqv6UWMw8pX4lhHaMiW7JP82MmKm91znItrEWgiPR1HT8EdlPgqkbtQFKHwJSSgSZ4RCyrdIjvu4MenzO03WniuSfUWsn7RFKkKp68HtA9mxlrs2dohP2b_Vrl52MgoQZKmBhmc=">publication of the FELIX trial data in the New England Journal of Medicine</a>. In addition, the inclusion of AUCATZYL&#xAE; in the NCCN Guidelines, noting the lack of REMS program associated with our therapy, provides further validation of the demonstrated clinical benefit, favorable safety profile and the potential impact of the therapy for patients in need," said Dr. Christian Itin, Chief Executive Officer of Autolus. "We are executing to plan with the commercial launch and are encouraged to enter the year with 24 authorized treatment centers out of the 30 we anticipated by end of Q1."
"With the AUCATZYL&#xAE; launch on track, we look forward to updating the market on additional clinical pipeline programs that we believe will drive future growth," Dr. Itin continued. "In the second half of 2024, we undertook an R&amp;D portfolio review to evaluate the highest priority areas for strategic investment. In our upcoming R&amp;D investor event we will provide an outlook and plan to share initial data from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE)."

Government

Regulations

AUTL

Autolus Reports FDA Approval and NCCN Inclusion of AUCATZYL, Sets Milestones for Pipeline Growth

Nu Skin Enterprises Expects Q4 Preliminary Revenue At High End Of Company's Guidance Range

Upcoming Milestones
During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress with its other programs including a broad-acting antiviral against flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers.
Also during this time data may be reported from the ongoing MDACC clinical trial in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who previously failed or relapsed after hypomethylating agent therapy.
About the Proposed Transaction
Definitive agreements were executed with unanimous approvals by the Boards of Directors of Salarius Pharmaceuticals and Decoy Therapeutics. The closing consideration will consist primarily of nonvoting preferred stock of Salarius, and it is expected that following closing and a post-closing stockholder vote to approve the conversion of the preferred shares into common stock, Decoy investors would own approximately 86% of the outstanding shares of the merged company and Salarius stockholders would own approximately 14% of the outstanding shares, subject to adjustment, in each case exclusive of any shares issued in any subsequent financing. For further details on the transaction and conditions for closing of the merger, please refer to the Form 8-K Salarius Pharmaceuticals filed with the U.S. Securities and Exchange Commission (SEC) in conjunction with this press release at <a href="https://www.globenewswire.com/Tracker?data=yeDPyTXgkmZSvAFhlypNi1E_NSVoGXkqJHwo85x863b7TAHxb94RkX7PFTS7EXKjZC2HY5zvsEdQZrYYBPCs1Q==">www.sec.gov</a>.

SLRX

Salarius And Decoy Announces Merger, Decoy To Hold 86% Post-Conversion; Lead Asset To File IND With FDA; Advancements In Broad-Acting Antiviral And Peptide Drug Conjugate; Data Expected From MDACC Trial

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

EYPT

EyePoint Expects Cash Runway Into 2027 Beyond Topline DURAVYU Phase 3 Wet AMD Data Expected In 2026

Preliminary Unaudited Fourth Quarter and 2024 Revenue Results
Establishment Labs also announced preliminary unaudited results for fiscal year 2024:
<ul>
<li>2024 revenue is expected to be between $166.0 million and $166.5 million.</li>
<li>Revenue for the quarter ended December 31, 2024 is expected to be between $44.5 million and $45.0 million, including approximately $3.2 million from Motiva sales in the United States.</li>
</ul>

Management

ESTA

Establishment Labs Announces Peter Caldini To Become Interim CEO Effective March 1, 2025; Anticipates 2024 Revenue Between $166M-$166.5M, Q4 Revenue Between $44.5M-$45M; $3.2M From U.S. Motiva Sales

SYRE

Spyre Therapeutics Anticipates Cash Runway Into H2 2028; Expects Phase 1 Results For SPY002 In Q2 2025

Preliminary Fourth Quarter 2024 Financial Results
<ul>
<li>Product revenue: Preliminary neffy net product revenue for the fourth quarter of 2024 was approximately $6.5 million, with total net product sales for 2024 of approximately $7.1 million since neffy became available to wholesalers and pharmacies on September 23, 2024. More than 14,500 neffy two-pack units were delivered in the fourth quarter of 2024, including more than 1,500 units in the last week of 2024.</li>
<li>Cash position: Cash, cash equivalents and short-term investments were approximately $314.0 million as of December 31, 2024. ARS Pharma reiterates its guidance that the company expects its cash, cash equivalents and short-term investments to be sufficient to fund its current operating plan for at least three years.</li>
</ul>
2025 Key Strategic Priorities for Accelerating neffy U.S. Sales and Recent Highlights
<ul>
<li>Increase demand and traction among target prescribers, with continued sales force and medical science liaison engagement, expansion of the company's neffy Experience Program, and rollout of additional continuing medical education (CME) programs
<ul>
<li>More than 3,000 healthcare providers have prescribed neffy to date, of which 80 percent are in the highest decile categories for prescribing epinephrine</li>
<li>More than 1,750 healthcare providers have participated in the neffy Experience Program</li>
</ul>
</li>
<li>Expand commercial access of neffy
<ul>
<li>Express Scripts, the second largest pharmacy benefits manager in the U.S., added neffy to its commercial national formularies in November 2024</li>
<li>On track for more than 60 percent commercial coverage by the end of the first quarter of 2025, and more than 80 percent commercial coverage by the end of the third quarter of 2025</li>
<li>Contracting consistent with target long-term total gross-to-net revenue of 50 percent</li>
</ul>
</li>
<li>Increase consumer awareness of neffy and availability of a needle-free option
<ul>
<li>Preparations are underway to launch a branded neffy direct-to-consumer marketing campaign beginning in May 2025</li>
<li>Designed to build momentum ahead of the ‘back-to-school' season, the campaign will extend throughout the summer, driving brand recognition and encouraging patients to request neffy by name</li>
<li>In parallel, to amplify public awareness of the needle-free epinephrine option, Food Allergy Research and Education (FARE) is set to launch a public service announcement campaign featuring a celebrity ambassador with ARS Pharma support later this year</li>
</ul>
</li>
<li>Obtain approval of neffy 1 mg for children who weigh 15 to 30 kg
<ul>
<li>The sNDA filed with the U.S. FDA for neffy for children who weigh 15 to 30 kg has a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025</li>
<li>Based on review timelines and subject to approval, product availability of neffy 1 mg is expected in the second quarter of 2025</li>
</ul>
</li>
</ul>

SPRY

ARS Pharma Announces Preliminary Q4 2024 Results With Neffy Revenue At $6.5M; 14.5K Units Delivered. Cash Reserves At $314M To Fund Operations For 3 Years; 2025 Strategy Includes Expanding Neffy Access, Increasing Awareness, And Seeking FDA Approval For Neffy 1mg For Children

JP Morgan analyst Ella Smith upgrades LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) from Underweight to Overweight and raises the price target from $8 to $9.

Upgrades

JP Morgan Upgrades LegalZoom.com to Overweight, Raises Price Target to $9

BITF

BTBT

BTCS

BTCT

BTDR

CIFR

CLSK

COIN

Core Scientific, Inc. - Class A Common Stock

CORZ

HIVE

IREN

MARA

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MSTR

RIOT

WULF

Shares of crypto-related companies are trading lower amid a drop in Bitcoin.

Stephens &amp; Co. analyst Jim Salera reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $62 price target.

Reiteration

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target

CPI Aerostructures, Inc. ("CPI Aero&#xAE;" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVU#NYSE">CVU</a>) announced today that Raytheon Technologies authorized CPI Aero to begin manufacturing of pod structures and air management system components for the follow-on Lot 4 Production phase of the Next Generation Jammer Mid-Band (NGJ-MB) program. The binding notification provides a maximum value of $33.4 million.
Raytheon Technologies is manufacturing and delivering NGJ-MB, a technologically superior, all-aspect, high-power offensive airborne electronic attack system able to achieve force-level spectrum superiority in modern Anti-Access/Area Denial environments. NGJ-MB enhances existing EA-18G and F/A-18E/F cooperation to increase kinetic engagement capacity. There are two NGJ-MB pods per EA-18G aircraft. CPI Aero is delivering the Pod Structure and associated Air Management Systems (AMS). In June 2021, the NGJ-MB program reached Milestone C, indicating the system is ready for production. LRIP 1 was awarded July 2021, and LRIP 2 was awarded December 2021. LRIP 3 production phase was awarded May 2023. The Lot 4 contract announced today supports production of 34 Pods with deliveries commencing in the second half of 2025.

Contracts

CPI Aero Announces $33.4M Deal With Raytheon Technologies For Next Gen Jammer Mid-Band Lot 4 Production; 34 Pods Delivery Starting H2 2025

SOBR Safe, MicroCloud Hologram, and WiMi Hologram Cloud are the 3 Penny Stocks to watch now, based on TipRanks' Penny Stock Screener tool. Penny st...

3 Penny Stocks to Watch Now

MicroAlgo, Nauticus Robotics, and Faraday Future Intelligent Electric are the 3 Penny Stocks to watch on June 13, based on&nbsp;TipRanks' Penny Sto...

3 Penny Stocks to Watch Now, 6/13/24

A substantial stake acquisition in any company can significantly boost investor sentiment. If the company in question is a penny stock with a marke...

Here's Why MicroAlgo Shares Are Flying Higher This Week

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you want to adjust your investment portfolio to stay with the times, look no further. 



For many, augmented reality (AR) stocks are a novelty. The AR industry is forecasted to <a href="https://www.skyquestt.com/report/augmented-reality-market#:~:text=Augmented%20Reality%20(AR)%20Market%20was,period%20(2024%2D2031).">grow by 33.5% annually until 2031</a>, illustrating its secular growth prospects. Also, numerous AR stocks are backed by systematic factors, allowing investors to generate superior returns.



Despite the industry&rsquo;s potential, undervalued AR stocks are few and far between, as information about the industry is widely dispensed. Therefore, I journeyed to find three overlooked and underpriced augmented reality stocks. My screen focused on fundamental aspects, company-specific events and technical analysis. Moreover, I factored in valuation multiples to ensure a holistic analysis.



Importantly, augmented reality stocks are risky, meaning investors should be willing and able to take risks before investing in them. However, if you&rsquo;re a risk-seeking investor like me, then examine three augmented reality stocks worth considering.



<h2>Vuzix Corp. (VUZI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/11/vuzi-stock-1-300x169.jpg" alt="Vuzix (VUZI) branded AR glasses"><div>Source: zixia / Shutterstock.com</div></div>Vuzix (NASDAQ:<a href="https://investorplace.com/stock-quotes/vuzi-stock-quote/">VUZI</a>) is a vertically integrated augmented reality company servicing numerous end markets, including security, defense, and enterprise clients. The company was <a href="https://ir.vuzix.com/company-information/company-history#:~:text=Our%20History,UK%3B%20and%20Tokyo%2C%20Japan.">founded in 1997</a>, but its product line only recently started to flourish amid a shift in the consumer environment.



I have much hope for VUZI stock, as I expect it to benefit from lucrative end markets and financial market-based support. Furthermore, Vuzix has formed critical partnerships, allowing it to scale. For example, the company <a href="https://www.vuzix.com/blogs/press-releases/vuzix-and-avegant-announce-strategic-partnership-to-develop-full-color-optical-reference-design-for-ai-enabled-consumer-smart-glasses">recently partnered with Avegant</a> to develop and supply optical modules. And additional partnerships may be in the offing, given Vuzix&rsquo;s nimble yet orchestrated business model.



VUZI stock has <a href="https://investorplace.com/stock-quotes/vuzi-stock-quote/">lost more than 40%</a> in the past six months, largely due to <a href="https://www.marketwatch.com/investing/stock/vuzi/analystestimates">consecutive quarterly earnings misses</a>. However, VUZI stock&rsquo;s forward price-to-sales <a href="https://seekingalpha.com/symbol/VUZI/valuation/metrics">ratio of 7.8x is approximately 65.68%</a> lower than its five-year average, suggesting it is relatively undervalued. Moreover, VUZI stock recently breached its <a href="https://seekingalpha.com/symbol/VUZI/momentum/performance">ten- and 50-day moving averages</a>, indicating that it has reached a support level.



In essence, Vuzix is a contrarian stock with secular prospects. I&rsquo;m bullish here!



<h2>Nextech3D.ai. (NEXCF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/ai1600c-300x169.jpg" alt="AI stocks"><div>Source: Shutterstock</div></div>Nextech3D.ai (OTCMKTS:<a href="https://investorplace.com/stock-quotes/nexcf-stock-quote/">NEXCF</a>) is a high-quality artificial intelligence (AI) image generator. The company provides strong value propositions, including cost-saving, time efficiency and dynamic image generation. Although in its early stages, Nextech3D.ai might experience tremendous traction in the coming years, allowing it to scale its operations.



Recently, the company proved its worth by delivering a promising first-quarter earnings report. Nextech3D.ai achieved <a href="https://www.accesswire.com/867536/nextech3dai-reports-q1-2024-revenue-of-1024000-with-gross-profit-margin-of-51-or-526212-a-70-jump-over-2023" target="_blank">C$1.02 million</a> (approximately $750,000) in quarterly revenue, illustrating its use case. Additionally, the company&rsquo;s gross profit margin grew by an impressive 70% year-over-year (YOY)to 51%.



I like the look of this company, as it has a bright concept and a margin expansion story. As mentioned before, Nextech3D.ai&rsquo;s first-quarter gross profit margin expanded. However, the company anticipated additional enhancements due to its cost-cutting program. In fact, it forecasts its gross profit margin to settle between 70% and 80% by its next reporting quarter.



Lastly, NEXCF has a sound valuation outlook. For instance, it has a price-to-sales ratio of <a target="_blank" href="https://finance.yahoo.com/quote/NEXCF/key-statistics/">1.84x</a>, which is exceptionally low for a company with Nextech3D.ai&rsquo;s growth potential.



<h2>WiMi Hologram Cloud (WIMI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/wimi-stock-300x169.jpg" alt="Holographic earth and digital pattern. representing WiMi Hologram Cloud Stock"><div>Source: Shutterstock</div></div>WiMi Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) is a holographic augmented reality platform that provides advertising and entertainment services. The company aims to become China&rsquo;s largest holographic ecology, which is no easy feat but lucrative if successful. 



I decided to include WIMI stock on the list as it provides a diversification tool via its exposure to China. Moreover, WiMi Hologram Cloud operates in a highly skilled domain, meaning it is protected by high barriers to entry.



WiMi Hologram Cloud released its full-year earnings report in April, revealing <a href="https://www.sahmcapital.com/news/content/wimi-hologram-cloud-full-year-2023-earnings-cn483-loss-per-share-vs-cn415-loss-in-fy-2022-2024-04-27">CN&yen;585.4m</a> (approximately $80 million) in revenue and a net loss of CN&yen;421.2m (approximately $58 million). Although its financial results are shaky, I anticipate the firm&rsquo;s fundamentals will improve in the next few years as it consolidates its market share via succinct product development.



It is needless to say that WIMI stock has its flaws. However, it provides an excellent early-stage opportunity, especially considering it has a <a href="https://finance.yahoo.com/quote/WIMI/key-statistics/">price-to-sales ratio of merely 0.88x</a>.



On the date of publication, Steve Booyens did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Steve Booyens co-founded Pearl Gray Equity and Research in 2020 and has been responsible for cross-asset research and PR ever since. Before founding the firm, Steve spent time working in various finance roles in London and South Africa. He holds an MSc in Investment Banking from Queen Mary &ndash; University of London. Furthermore, Steve obtained his CFA Charter on April 26, 2024, and is working toward his Ph.D. in Finance. His articles are published on various reputable web pages such as Seeking Alpha, TipRanks, Yahoo Finance, and Benzinga. Steve&rsquo;s articles on InvestorPlace form an interesting juxtaposition between mainstream opinion and objective theory. Readers can expect coverage on frequently traded stocks, REITs, fixed-income funds, CEFs, and ETFs.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/youve-been-warned-3-augmented-reality-stocks-to-buy-now-or-regret-forever/">You&#8217;ve Been Warned! 3 Augmented Reality Stocks to Buy Now or Regret Forever.</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

You've Been Warned! 3 Augmented Reality Stocks to Buy Now or Regret Forever.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!



Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chuy&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/chuy-stock-quote/">CHUY</a>) stock is rocketing more than 46% on a <a href="https://www.nasdaq.com/press-release/darden-restaurants-acquire-chuys-holdings-inc-approximately-605-million-transaction">$605 million acquisition deal</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) shares are soaring over 43% alongside heavy pre-market trading.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is surging more than 25% with strong early morning trading.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are rising over 23% as it <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">kicks off a Phase 3 clinical trial</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is increasing more than 18% with strong pre-market trading.</li>



<li>ZimVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/zimv-stock-quote/">ZIMV</a>) shares are heading over 13% higher without any clear news on Thursday morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is gaining more than 12% on a <a href="https://www.globenewswire.com/news-release/2024/07/18/2914992/0/en/SAI-TECH-Global-Corporation-Announces-Share-Repurchase-Program.html">share repurchase program</a>.</li>



<li>MultiMetaVerse (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmv-stock-quote/">MMV</a>) shares are climbing over 11% as it continues a recent rally.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is jumping more than 10% despite a lack of news today.</li>



<li>XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) shares are up over 10% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Leslies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lesl-stock-quote/">LESL</a>) stock is diving more than 21% on <a href="https://www.nasdaq.com/press-release/leslies-inc-announces-preliminary-third-quarter-fiscal-2024-financial-results-and">preliminary earnings and guidance</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rumbling over 13% after a massive rally yesterday.</li>



<li>Domino&rsquo;s Pizza (NYSE:<a href="https://investorplace.com/stock-quotes/dpz-stock-quote/">DPZ</a>) stock is sliding more than 13% with the release of its <a href="https://ir.dominos.com/static-files/68ecdbfc-bd1c-486a-a574-d6f54b7e5132">Q2 earnings report</a>.</li>



<li>CBL International (NASDAQ:<a href="https://investorplace.com/stock-quotes/banl-stock-quote/">BANL</a>) shares are taking an over 12% beating on Thursday morning as it retreats from a rally yesterday.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) stock is dropping close to 12% after an unexpected rally yesterday.</li>



<li>Beyond Meat (NASDAQ:<a href="https://investorplace.com/stock-quotes/bynd-stock-quote/">BYND</a>) shares are falling more than 11% on <a href="https://www.wsj.com/articles/beyond-meat-engages-bondholders-for-restructuring-talks-7de6b8ae">restructuring talks with bondholders</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is decreasing over 11% this morning after rallying on Wednesday.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are slipping more than 10% <a href="https://investorplace.com/2024/07/why-is-aditxt-adtx-stock-up-72-today/">following a rally yesterday</a>.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is dipping over 10% <a href="https://investorplace.com/2024/07/stardust-power-sdst-stock-pops-140-days-after-debut-what-to-know/">after a surprise rally yesterday</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

WiMi Hologram Cloud (WIMI) has released an update. WiMi Hologram Cloud Inc. has reported an increase in its total assets, reaching RMB 1,425.7 mill...

WiMi Hologram Cloud Reports Asset and Liability Growth

WiMi Hologram Cloud reports 1H results

WiMi Hologram Cloud (WIMI) has released an update. WiMi Hologram Cloud Inc. has received a notification from Nasdaq indicating that its stock has b...

WiMi Hologram Faces Nasdaq Compliance Challenge

Unusual total active option classes on open include: WiMi Hologram Cloud (WIMI), Accenture (ACN), Coherent (COHR), ARK Genomic Revolution Multi Sec...

Unusually active option classes on open December 19th

Latest data shows the largest indicative borrow rate increases among liquid option names include: Mesoblast (MESO) 535.67% +298.96, Aptiv (APTV) 54...

Largest borrow rate increases among liquid names

ADTX

AISP

APLM

APTV

APVO

AREB

ARKG

BANL

BBAI

BNOX

BYND

CHUY

COHR

FFIE

GOEV

HIMS

HOLO

KITT

LESL

MEOBF

MESO

MLGO

NEXCF

ONCO

RCAT

RGTI

SDST

SOBR

TNYA

XWEL

ZIMV

Entertainment

Press Releases

WiMi Researches A Blockchain-Assisted Resource Management Scheme for Edge Computing Networks

WiMi Explores Smart Contract-Driven Cross-Chain Communication Technology to Build an Interconnected Blockchain Ecosystem

WiMi Explores Blockchain-Based Distributed Collaborative Computing

WiMi Deploys Cross-Chain Model Based on Relay Chain and Asynchronous Consensus Mechanism

WiMi Develops a New Design Solution for Simulating Quantum Computing Concepts Using FPGA

WiMi Develops FPGA-Based Digital Quantum Computer Verification Technology

WiMi Researches Quantum Linear Solvers, A Resource-Efficient Quantum Algorithm for Linear Systems of Equations

WiMi Develops Quantum Error Mitigation Technology Based on Machine Learning

WiMi Develops a Quantum Technology-Based Random Access Memory Architecture

WiMi Develops FPGA-Based Homogeneous and Heterogeneous Digital Quantum Coprocessors

Comments

WiMi Hologram Cloud

WiMi Hologram Cloud (WIMI) Forecast

WiMi Hologram Cloud (NASDAQ:WIMI) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga